Indoco Remedies Management Meet Takeaways - Growth Guidance Intact: Nirmal Bang
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Nirmal Bang Report
We hosted the management of Indoco Remedies Ltd. for an investor interaction. The key takeaways from our discussion are as follows:
active pharma ingredient prices have been rising incessantly from the beginning of October 2021,
shortage of glass vials for its injectable products, as majority of the vials is used for Covid-19 vaccines,
shortage of incoming containers from China.
It has been a challenge to source products from the global markets, which has also led to higher container costs and delay in shipments. Although the company has actively tried to mitigate risks, raw material inflation and freight costs may still have some residual impact on margins.
Indoco Remedies expects some easing of the two challenges by the end of January 2022 and is confident about a better Q4 FY22.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.